4-叔丁基-2-甲基嘧啶-5-羧酸乙酯 | 127957-91-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-叔丁基-2-甲基嘧啶-5-羧酸乙酯
• 英文名称: ethyl 4-tert-butyl-2-methylpyrimidine-5-carboxylate
• CAS: 127957-91-9
• 化学式: C₁₂H₁₈N₂O₂
• 分子量: 222.287
• InChiKey: QKIJBTSRQMNSOY-UHFFFAOYSA-N

物化性质

• 沸点：
  85-90 °C(Press: 0.7 Torr)
• 密度：
  1.042±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-叔丁基-2-甲基嘧啶-5-羧酸乙酯 在 氢氧化钾 作用下， 以 甲醇 为溶剂， 反应 5.0h， 以77%的产率得到4-叔丁基-2-甲基嘧啶-5-羧酸
  参考文献：
  名称：

  Schenone, Pietro; Sansebastiano, Laura; Mosti, Luisa, Journal of Heterocyclic Chemistry, 1990, vol. 27, # 2, p. 295 - 305

  摘要：

  DOI：
• 作为产物：
  描述：

  特戊酰基乙酸乙酯 在 sodium methylate 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 11.0h， 生成 4-叔丁基-2-甲基嘧啶-5-羧酸乙酯
  参考文献：
  名称：

  Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors

  摘要：

  11 beta-HSD1 is increasingly seen as an attractive target for the treatment of type II diabetes and other elements of the metabolic syndrome. In this program of work we describe how a series of neutral 2-thioalkyl-pyridine 11 beta-HSD1 inhibitors were optimized in terms of their pharmacokinetic properties to give compounds with excellent bioavailability in both rat and dog through a core change to pyrimidine. A potential reactive metabolite issue with 4-thioalkyl-pyrimidines was circumvented by a switch from sulfur to carbon substitution. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.08.070

文献信息

• SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281
  申请人：GILL Adrian Liam

  公开号：US20090264401A1

  公开（公告）日：2009-10-22

  A compound of formula (I): and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.

  一种具有化学式（I）的化合物： 及其药用盐，其中变量基团在其中定义；还描述了它们在抑制11βHSD1中的应用，制备它们的方法以及包含它们的药物组合物。
• SCHENONE, PIETRO;SANSEBASTIANO, LAURA;MOSTI, LUISA, J. HETEROCYCL. CHEM., 27,(1990) N, C. 295-305
  作者：SCHENONE, PIETRO、SANSEBASTIANO, LAURA、MOSTI, LUISA

  DOI：——

  日期：——
• [EN] SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281<br/>[FR] PYRIMIDINE-5-CARBOXAMIDES SUBSTITUÉS
  申请人：ASTRAZENECA AB

  公开号：WO2009130496A1

  公开（公告）日：2009-10-29

  A compound of formula (I) and pharmaceutically-acceptable salts thereof wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described.
• Optimisation of pharmacokinetic properties in a neutral series of 11β-HSD1 inhibitors
  作者：James S. Scott、Adrian L. Gill、Linda Godfrey、Sam D. Groombridge、Amanda Rees、John Revill、Paul Schofield、Pernilla Sörme、Andrew Stocker、John G. Swales、Paul R.O. Whittamore

  DOI：10.1016/j.bmcl.2012.08.070

  日期：2012.11

  11 beta-HSD1 is increasingly seen as an attractive target for the treatment of type II diabetes and other elements of the metabolic syndrome. In this program of work we describe how a series of neutral 2-thioalkyl-pyridine 11 beta-HSD1 inhibitors were optimized in terms of their pharmacokinetic properties to give compounds with excellent bioavailability in both rat and dog through a core change to pyrimidine. A potential reactive metabolite issue with 4-thioalkyl-pyrimidines was circumvented by a switch from sulfur to carbon substitution. (C) 2012 Elsevier Ltd. All rights reserved.
• Schenone, Pietro; Sansebastiano, Laura; Mosti, Luisa, Journal of Heterocyclic Chemistry, 1990, vol. 27, # 2, p. 295 - 305
  作者：Schenone, Pietro、Sansebastiano, Laura、Mosti, Luisa

  DOI：——

  日期：——